Lonza agreed to buy a manufacturing facility in the U.S. from Roche for around $1.2 billion in cash as it seeks to boost growth of its biologics division. The deal, due to close in the second half ...

(Reuters) -Swiss contract drug manufacturer Lonza said on Wednesday it would buy one of the world's largest manufacturing sites for biologic drugs in California from drugmaker Roche for $1.2 billion.

Jan 25 (Reuters) - Lonza (LONN.S), opens new tab on Wednesday said it will buy back shares worth 2 billion Swiss francs ($2.17 billion), despite an expected drop in annual margins, as the Swiss ...

There are limited tariff risks. Lonza is a potential beneficiary given the ample availability of the USA industrial capacities should biotech or pharma have onshoring needs. With profit growth ...

Lonza Group announced Monday morning that Pierre-Alain Ruffieux will leave his post as CEO at the end of the month. Ruffieux, a former Roche executive, joined Lonza in 2020 and oversaw the company’s ...

Lonza shares rise 6.7% after CHI exit announcement Company to focus on CDMO business restructuring Plans M&A for tech and capacity opportunities Dec 12 (Reuters) - Swiss contract drugmaker Lonza ...

Lonza, the Swiss Biotech firm that purchased Vacaville’s Genentech plant from Roche in 2024, released a streamlined operating model and invitations to its Annual General Meeting in Basel ...

Swiss Biotechnology firm Lonza, which purchased the Genentech facility in Vacaville last year, reported an income of 6.6 billion in Swiss francs (CHF) for the year 2024, which converts to about $7 ...

Swiss CDMO powerhouse Lonza is on a roll. Right after revealing a manufacturing expansion set to create nearly 200 new jobs, the CDMO has unveiled an expanded collaboration with an unnamed ...

Lonza’s search for a CEO has led the Swiss CDMO giant to its compatriot competitor, Siegfried. Lonza has poached Siegfried’s helmsman Wolfgang Wienand as its own CEO, the company said Tuesday.